<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Revolutionizing Cancer Drug Combination Discovery with AI: Introducing SynAI

I am excited to share with you a significant advancement in the field of cancer research, the culmination of recent efforts by my team and me. We have published our study on "SynAI" in the journal "Bioinformatics Advances" (November 2023). SynAI is an AI-driven platform designed to predict the synergistic effects of cancer drug combinations, poised to fundamentally change how we discover and evaluate cancer treatments.

Understanding SynAI: A Major Leap in Cancer Treatment

At its heart, SynAI is about predicting the combined effects of cancer drugs, known as drug synergism. This AI-driven solution is flexible and innovative, focusing on early-stage drug discovery to identify the therapeutic potential of various compound combinations.

Unlike traditional approaches, SynAI does not rely on actual drug combinations or specific cell lines. Instead, it utilizes the Simplified Molecular Input Line Entry System (SMILES) sequences of compounds. Our AI model, trained with over 1.2 million in vitro tests across different cancer cell lines, predicts potential synergisms or antagonisms between drug combinations without the need for costly and time-consuming physical synthesis or structural analysis.

Figure 1. Samples of the SynAI interface, where you can select the target cell
line and the drug combination of interest for drug synergy prediction.


How SynAI Benefits Cancer Research

  • Cost-efficiency: By using only SMILES sequences, SynAI significantly reduces the costs associated with candidate screening during drug development.
  • Time-saving: The computational predictions eliminate the need for physical compound synthesis, speeding up the initial screening process.
  • Flexibility and Adaptability: Our AI model is retrainable, meaning it can continuously adapt and improve with new data, making it a future-proof tool in the battle against cancer.

SynAI's Unique Features

  • Multi-input Modes: SynAI offers four input modes to cater to different research needs and allows for bulk processing through an API.
  • Robust AI Core: The platform’s AI core, built on a multi-layer perceptron network, has undergone rigorous training and testing.
  • Predictive Accuracy: Our model uniquely handles SMILES sequences, ensuring accurate predictions regardless of the compound order.
  • Retrainable and Adaptive AI Core: SynAI's AI core is not static; it's retrainable and adaptive. This means that any new experimental data can be seamlessly integrated into the core to reinforce prediction coverage and enhance accuracy over time. This dynamic feature ensures that SynAI continuously improves its performance as more data becomes available, making it a powerful tool for cutting-edge research.

The Future of Personalized Medicine

The potential of SynAI extends beyond its current applications. We plan to incorporate organoid and clinical data, paving the way for personalized medicine. Imagine a future where cancer treatment is tailored to the individual, maximizing therapeutic efficiency and minimizing side effects.

Conclusion: A Step Towards a Brighter Future

In conclusion, SynAI stands out not only for its current capabilities but also for its potential to evolve with ongoing research. It's more than a platform; it's a beacon of hope in our continuous fight against cancer.

CrownSyn™ Drug combination Analysis Service Image
LEARN MORE
SynAI: An AI-driven Cancer Drugs Synergism Prediction Platform Image
Download Now

Interested in SynAI?

GET FREE ACCESS


Related Posts